Dyslipidemia
Episodes 1-16 of 21
Erik Stroes, MD, PhD
P. Gabriel Steg, MD
Pam R. Taub, MD, FACC, FASPC
P. Gabriel Steg, MD
Pam R. Taub, MD, FACC, FASPC
Erik Stroes, MD, PhD
Fabrice Martens, MD, PhD, FESC
- MinuteCE®
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
1.00 program creditErin D. Michos, MD, MHS, FACC, FAHA, FASE
Prof. Kausik Ray, MBChB, MD, MPhil
Lale Tokgözoğlu, MD
Fabrice Martens, MD, PhD, FESC
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
- MinuteCE®
The evolving need and challenges to reach LDL-c targets in high-risk patients
1.00 program creditProf. Kausik Ray, MBChB, MD, MPhil
Lale Tokgözoğlu, MD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
- MinuteCE®
New insights on CETP inhibition from genetic research and clinical trials
1.00 program creditJohn Kastelein, MD, PhD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
John Kastelein, MD, PhD
Roxana Mehran, MD
Roxana Mehran, MD
Lale Tokgözoğlu, MD
- MinuteCE®
Integrating icosapent ethyl in preventive strategies: Practical guidance
1.00 program creditVictor Aboyans, MD, PhD
Richard Hobbs, MD
- Prev
- Next